198 related articles for article (PubMed ID: 26644449)
1. Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.
Mick R; Chen TT
Cancer Immunol Res; 2015 Dec; 3(12):1292-8. PubMed ID: 26644449
[TBL] [Abstract][Full Text] [Related]
2. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.
Chen TT
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26113579
[TBL] [Abstract][Full Text] [Related]
3. Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?
Chen TT
Cancer Immunol Res; 2018 Mar; 6(3):250-254. PubMed ID: 31343973
[TBL] [Abstract][Full Text] [Related]
4. Approaches to improve development methods for therapeutic cancer vaccines.
Ogi C; Aruga A
Immunol Lett; 2015 Apr; 164(2):100-8. PubMed ID: 25746315
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and current challenges in tumor immunology and immunotherapy.
Guinn BA; Kasahara N; Farzaneh F; Habib NA; Norris JS; Deisseroth AB
Mol Ther; 2007 Jun; 15(6):1065-71. PubMed ID: 17375068
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in cancer immunology and immunology-based anticancer therapies.
Kumar S; Saini RV; Mahindroo N
Biomed Pharmacother; 2017 Dec; 96():1491-1500. PubMed ID: 29198747
[TBL] [Abstract][Full Text] [Related]
7. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.
Brockstedt DG; Dubensky TW
Expert Rev Vaccines; 2008 Sep; 7(7):1069-84. PubMed ID: 18767955
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?
Fry TJ; Lankester AC
Pediatr Clin North Am; 2008 Feb; 55(1):147-67, xi. PubMed ID: 18242319
[TBL] [Abstract][Full Text] [Related]
9. Various ways to improve whole cancer cell vaccines.
Cicchelero L; de Rooster H; Sanders NN
Expert Rev Vaccines; 2014 Jun; 13(6):721-35. PubMed ID: 24758597
[TBL] [Abstract][Full Text] [Related]
10. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.
Hege KM; Jooss K; Pardoll D
Int Rev Immunol; 2006; 25(5-6):321-52. PubMed ID: 17169779
[TBL] [Abstract][Full Text] [Related]
11. Evolution of end points for cancer immunotherapy trials.
Hoos A
Ann Oncol; 2012 Sep; 23 Suppl 8():viii47-52. PubMed ID: 22918928
[TBL] [Abstract][Full Text] [Related]
12. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.
Mellman I; Hubbard-Lucey VM; Tontonoz MJ; Kalos MD; Chen DS; Allison JP; Drake CG; Levitsky H; Lonberg N; van der Burg SH; Fearon DT; Wherry EJ; Lowy I; Vonderheide RH; Hwu P
Cancer Immunol Res; 2016 Apr; 4(4):279-88. PubMed ID: 27036972
[TBL] [Abstract][Full Text] [Related]
13. Spinning molecular immunology into successful immunotherapy.
Pardoll DM
Nat Rev Immunol; 2002 Apr; 2(4):227-38. PubMed ID: 12001994
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N; Zoernig I; Jäger D
Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
[TBL] [Abstract][Full Text] [Related]
15. Cancer vaccines: what do we need to measure in clinical trials?
Kudrin A
Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
[TBL] [Abstract][Full Text] [Related]
16. Improving the efficacy of cancer immunotherapy.
Copier J; Dalgleish AG; Britten CM; Finke LH; Gaudernack G; Gnjatic S; Kallen K; Kiessling R; Schuessler-Lenz M; Singh H; Talmadge J; Zwierzina H; Håkansson L
Eur J Cancer; 2009 May; 45(8):1424-31. PubMed ID: 19167214
[TBL] [Abstract][Full Text] [Related]
17. Improved endpoints for cancer immunotherapy trials.
Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in anticancer responses.
Whelan M
Curr Opin Mol Ther; 2004 Feb; 6(1):8-9. PubMed ID: 15011775
[No Abstract] [Full Text] [Related]
19. Predicting analysis times in randomized clinical trials with cancer immunotherapy.
Chen TT
BMC Med Res Methodol; 2016 Feb; 16():12. PubMed ID: 26830911
[TBL] [Abstract][Full Text] [Related]
20. [New directions in immunotherapy for malignant solid tumors].
Okuno K; Sugiura F; Sukegawa Y; Inoue K
Nihon Rinsho; 2012 Dec; 70(12):2075-86. PubMed ID: 23259377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
